Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review

Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review

Outlook Therapeutics has resubmitted its Biologics License Application (BLA) for LYTENAVA (bevacizumab-vikg) to the FDA, initiating a 60-day Class 1 review. This marks a critical step for the drug's potential approval in treating neovascular age-related macular degeneration (nAMD). For BD teams and investors tracking the ophthalmology pipeline, the resubmission represents a near-term catalyst with outsized implications for Outlook Therapeutics' commercial trajectory and the competitive wet AMD market.

Key Takeaways

• Outlook Therapeutics has resubmitted its BLA for LYTENAVA (bevacizumab-vikg) to the FDA, triggering a Class 1 review with a PDUFA decision expected within 60 days.
• LYTENAVA is an investigational ophthalmic formulation of bevacizumab intended for adult patients with neovascular (wet) age-related macular degeneration (nAMD).
• The resubmission follows a prior FDA decline on December 31, 2025, and positions LYTENAVA as a potential first-to-market FDA-approved ophthalmic bevacizumab formulation with 12 months of marketing exclusivity.
• A favorable decision could unlock significant commercial opportunities for Outlook Therapeutics (OTLK), making the asset a potential target for partnerships or acquisitions in the ophthalmology space.

Outlook Therapeutics Resubmits LYTENAVA BLA

Outlook Therapeutics has officially resubmitted its Biologics License Application for LYTENAVA (bevacizumab-vikg) to the FDA, a move that follows previous regulatory interactions including a prior complete response letter and a subsequent successful appeal. According to the company, the agency anticipates the resubmission will qualify as a Class 1 review, which typically carries a 60-day review timeline from the date of resubmission. Stock Titan reported the announcement on June 1, 2026, confirming the 60-day PDUFA decision window.

The resubmission places LYTENAVA back on the FDA drug tracker at a pivotal moment. Outlook Therapeutics had previously faced regulatory setbacks, with the FDA declining approval and citing insufficient evidence for the wet AMD indication. Reuters reported that the agency issued a complete response letter on December 31, 2025, marking a second decline for the asset. The company's successful appeal cleared the path for this resubmission, and the Class 1 designation signals that the FDA considers the response to be a complete response to the prior action letter — a classification that carries the shorter 60-day review clock rather than the standard 10-month timeline.

What Is LYTENAVA's Clinical Indication and Competitive Position?

LYTENAVA is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), a condition that causes abnormal blood vessel growth beneath the retina and is a leading cause of vision loss in older adults. The European Medicines Agency has granted marketing authorization for LYTENAVA for this same indication, confirming its regulatory recognition in the EU.

If the BLA is approved, ONS-5010/LYTENAVA would become the only FDA-approved ophthalmic bevacizumab formulation, securing 12 months of marketing exclusivity. According to a review published in PMC, an on-label bevacizumab product for retina use would fill a critical gap, as compounded bevacizumab has been widely used off-label in ophthalmology for years without formal FDA approval for ocular use. This exclusivity period could provide Outlook Therapeutics with a meaningful commercial moat in a market currently dominated by ranibizumab (Lucentis) and aflibercept (Eylea), along with newer entrants like faricimab (Vabysmo).

What Does the 60-Day Review Mean for Investors and BD Teams?

The 60-day review window is the most immediate catalyst for Outlook Therapeutics and its stakeholders. A Class 1 resubmission means the FDA has determined that the company's response addresses the deficiencies outlined in the prior action letter, and the agency aims to render a decision within two months. For investors holding OTLK, this is a binary event with significant upside potential — and corresponding risk if the agency issues another negative decision.

For business development teams, a potential FDA approval would transform LYTENAVA from an investigational asset into a commercial-stage product. The wet AMD market represents billions of dollars in annual revenue, and an approved ophthalmic bevacizumab formulation could capture meaningful share given its potential cost advantage over branded anti-VEGF therapies. BD teams at larger ophthalmology-focused companies should be evaluating LYTENAVA's competitive positioning, pricing strategy, and market access readiness as potential partnership or acquisition scenarios.

Analysts will be watching for the PDUFA date announcement and any pre-decision communications from the FDA. Outlook Therapeutics' ability to secure commercial manufacturing, build a sales force, or strike a partnership deal ahead of approval will be key factors in determining the drug's launch trajectory.

Frequently Asked Questions

Related profiles

• LYTENAVA
• Outlook

Related coverage

• FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development
• Biosimilars Drive Significant Reductions in Specialty Drug Spending
• Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug